Eli Lilly introduces chronic disease health book
INDIANAPOLIS Eli Lilly has unveiled a new product to help people battle chronic diseases. The product is a free pocket-sized health book titled, “A Healthy You! – America’s Guide to Healthy Living.”
Inside the 148-page health resource book, readers will find useful tips and information on key measures. Chapters include: exercise and nutrition, children’s health, women’s health, men’s health, older adults, mental health, diabetes, living heart healthy, cancer screening, substance abuse and tobacco cessation, veterans health, and patient assistance programs.
“If you’ve ever tried to learn about a healthcare issue, you have probably found an endless stream of information and resources. While this is encouraging, it can also be overwhelming,” said Jack Bailey, a vice president at Eli Lilly. “That’s exactly why we created this free book: to make it simple for Americans to find the answers they need to lead healthy lives.”
According to the Centers for Disease Control, chronic diseases account for 70 percent of all deaths in the United States, 1.7 million each year. These diseases also cause major limitations in daily living for almost 1-out-of-10 Americans, or about 25 million people.
Pfizer wins Celebrex patent challenge
NEW YORK Pfizer announced that the Court of Appeals for the Federal Circuit has upheld two main patents for the company’s anti-inflammatory drug Celebrex, according to published reports.
Teva had challenged the patents, but the court ruled that the patents are valid and enforceable, but they did rule that a third patent, covering the treatment of inflammation was invalid.
Nevertheless, the decision blocks Teva from launching a generic version until May 2014.
The drug had global sales of $1.7 billion in 2007. Bear Stearns analyst project that it will reach global sales of $2.5 billion in 2008, an increase of 9 percent, and that the drug will pull in $3.1 billion by 2012.
FDA to enhance warnings on Tussionex
WASHINGTON UCB, the maker of Tussionex cough medicine, has reached out to the Food and Drug Administration to place a stronger warning on the drug. This new push stems from the report of five deaths of young children from taking Tussionex.
According to published reports, the deaths were all children under age 6, but the Belgian pharmaceutical company said that the drug is only to be taken for children and adults ages 6 and up.
Tussionex Pennketic Extended- Release Suspension contains the pain reliever hydrocodone. According to reports, the FDA is planning to issue an alert about the effects of Tussionex.